Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.
11 slides
Latest News
OCT – diagnosis and prognosis
November 8, 2023ECTRIMS-ACTRIMS 2023 presented new data on the use of optical coherence tomography (OCT) as a biomarker in multiple sclerosis. The following is a brief summary of recent findings. Read More
Novel treatments: targeting CD40 ligand
November 1, 2023The transmembrane receptor CD40 and its ligand (CD40L or CD154) are involved in initiating and sustaining the inflammatory response. While these responses are beneficial in infection and tumour lysis, chronic activation has been implicated in a range of neuroinflammatory and autoimmune conditions, including MS, Alzheimer’s disease and Parkinson’s disease. Read More
ECTRIMS-ACTRIMS 2023 HIGHLIGHTS – FRIDAY, OCTOBER 13 EDITION
October 13, 20239th Joint ECTRIMS-ACTRIMS meeting – 11-13 October 2023
The following summarizes some of the highlights from Day 3 of ECTRIMS-ACTRIMS 2023.